Sutro Biopharma, Inc.(STRO)

$31.84—

Chart

Sutro Biopharma, Inc.(STRO)

NASDAQ

$31.84—

Chart Studio

STRO(STRO)

STRO

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-2.22

Aug 6, 2026 · Reports before open

Revenue Estimate

$12M

Analyst Sentiment

Wall St. Consensus

Buy

20 analysts·High coverage

Score

18 Buy (90%)1 Hold (5%)1 Sell (5%)

Rating Breakdown

Strong Buy

00%

Buy

1890%

Hold

15%

Sell

15%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$43.00

+35.1%

Consensus

$50.00

+57.0%

Bull

$60.00

+88.4%

12-Month Target Range20 analysts

$43.00$50.00$60.00

Current $31.84Consensus

Current Price

$31.84

Upside to Consensus

$18.16

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-22.73%

EPS—

FY2028

Rev+22.72%

EPS—

FY2029

Rev-1.38%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$45M	$34M	$42M	$42M	$69M
Low	$27M	$2M	$14M	$14M	$24M
High	$66M	$63M	$68M	$67M	$111M
EBITDA Avg	$-40M	$-31M	$-38M	$-37M	$-61M
Low	$-59M	$-56M	$-60M	$-60M	$-99M
High	$-24M	$-2M	$-13M	$-13M	$-21M
EBIT Avg	$-40M	$-31M	$-38M	$-37M	$-62M
Low	$-59M	$-56M	$-61M	$-60M	$-100M
High	$-24M	$-2M	$-13M	$-13M	$-21M
Net Income Avg	$-70M	$-65M	$-60M	$-57M	$-52M
Low	$-82M	$-89M	$-85M	$-101M	$-92M
High	$-59M	$-41M	$-35M	$-8M	$-7M
EPS Avg	$-8.53	$-7.39	$-7.24	$-6.66	$-6.07
Low	$-9.65	$-10.52	$-10.02	$-11.93	$-10.87
High	$-6.92	$-4.80	$-4.08	$-0.95	$-0.87
Analysts (Rev / EPS)	9 / 7	9 / 8	9 / 9	4 / 3	4 / 3

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$10M	$9M	$10M	$10M	$10M	$10M
Low	$2M	$2M	$2M	$2M	$2M	$2M
High	$17M	$15M	$17M	$17M	$17M	$17M
EBITDA Avg	$-9M	$-8M	$-9M	$-9M	$-9M	$-9M
Low	$-15M	$-13M	$-15M	$-15M	$-15M	$-15M
High	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M
EBIT Avg	$-9M	$-8M	$-9M	$-9M	$-9M	$-9M
Low	$-15M	$-13M	$-16M	$-15M	$-15M	$-15M
High	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M
Net Income Avg	$-268,720	$-243,169	$-284,561	$-275,732	$-260,560	$-255,717
Low	$-332,024	$-453,916	$-531,182	$-514,700	$-486,380	$-477,340
High	$-180,869	$2,701	$3,161	$3,063	$2,895	$2,841
EPS Avg	$-2.05	$-1.86	$-2.18	$-2.11	$-1.99	$-1.95
Low	$-2.54	$-3.47	$-4.06	$-3.93	$-3.72	$-3.65
High	$-1.38	$0.02	$0.02	$0.02	$0.02	$0.02
Analysts (Rev / EPS)	7 / 4	4 / 2	4 / 2	3 / 1	3 / 1	3 / 2

Earnings Surprises

Recent Analyst Actions

Jun 11, 2026Truist Financial

Sutro Biopharma assumed with a Buy at Truist

Target:$50.00

+91.6%from $26.09

May 28, 2026Barclays

Barclays Starts Sutro Biopharma (STRO) at Overweight

Target:$56.00

+88.6%from $29.69

May 15, 2026Wedbush

Sutro Biopharma upgraded to Outperform from Neutral at Wedbush

Target:$60.00

+56.2%from $38.42

May 15, 2026H.C. Wainwright

Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright

Target:$50.00

+30.1%from $38.42

May 15, 2026Leerink Partners

Sutro Biopharma price target raised to $43 from $38 at Leerink

Target:$43.00

+11.9%from $38.42

Apr 30, 2026Mizuho Securities

Sutro Biopharma initiated with an Outperform at Mizuho

Target:$50.00

+41.3%from $35.39

Mar 14, 2025Piper Sandler

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

Target:$2.00

-75.3%from $8.10

Oct 11, 2024Bank of America Securities

BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO)

Target:$12.00

-66.7%from $36.05

Oct 11, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO)

Target:$12.00

-66.8%from $36.10

Aug 16, 2024Truist Financial

Sutro Biopharma (STRO) PT Lowered to $15 at Truist Securities

Target:$15.00

-64.4%from $42.10

May 14, 2024Deutsche Bank

Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank

Target:$10.00

-77.0%from $43.40

May 14, 2024Wedbush

Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)

Target:$8.00

-81.1%from $42.30

Apr 3, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Sutro Biopharma (STRO)

Target:$10.00

-80.4%from $50.90

Apr 3, 2024Piper Sandler

Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler

Target:$11.00

-78.4%from $50.90

Apr 2, 2024Truist Financial

Sutro Biopharma (STRO) PT Lowered to $18 at Truist Securities

Target:$18.00

-64.6%from $50.90

Jan 13, 2023Truist Financial

Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25

Target:$25.00

-69.3%from $81.35

Jan 10, 2023Piper Sandler

Piper Sandler Maintains Overweight on Sutro Biopharma, Raises Price Target to $18

Target:$18.00

-78.3%from $82.90

Jun 28, 2022Piper Sandler

Sutro Biopharma price target raised to $16 from $14 at Piper Sandler

Target:$16.00

-68.3%from $50.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance